St. Jude Medical (NYSE:STJ) is launching a study to examine the economics of coronary interventions using fractional flow reserve in Japan, China, India, Korea, and Australia.

The analysis, based on the results of the Fame trial comparing FFR-guided procedures with those guided by angiography, plus statistics from country-specific percutaneous coronary intervention registries and other studies.